Setting the scene – a future ‘epidemic’ of immune-related adverse events in association with checkpoint inhibitor therapy

Abstract

Abstract Cancer immune therapy with checkpoint inhibitors (CPIs) has changed the landscape of treatment for a growing number of indications. These drugs are associated with a specific mechanism of action that has profound implications for both immunology and inflammatory disease. This article looks to set the scene covering the history of CPI therapy to date and outlining the likely future developments.